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ABSTRACT  1 
The technological and probiotic properties of the bile-adapted strain Bifidobacterium 2 
animalis subsp. lactis 4549dOx have been studied in comparison to its parental strain 3 
IPLA4549. The survival of the bile-adapted derivative to the simulated gastrointestinal transit 4 
was significantly higher than that of the parental strain, except in the presence of 10% 5 
skimmed milk. The adherence of strain 4549dOx to the intestinal cell line HT29-MTX almost 6 
duplicated that of strain IPLA4549. However, both strains have similar behaviour throughout 7 
the shelf-life of fermented milk. In conclusion, the bile-adapted strain 4549dOx presented, in 8 
conjunct, additional advantages for its inclusion in dairy probiotic foods.  9 
10 
 3
1. INTRODUCTION  1 
The term probiotic refers to live microorganisms which when administered in 2 
adequate amounts confer a health benefit on the host (FAO/WHO, 2006), their target being 3 
the human gastrointestinal tract (GIT). Probiotic Bifidobacterium strains are usually 4 
implemented as active cultures in fermented dairy products (Jayamanne & Adams, 2006) and, 5 
after being ingested, they must overcome the biological barriers of the GIT in order to  6 
We have obtained several bile-adapted bifidobacteria strains by progressive 7 
subcultures in gradually increasing bovine bile salt concentrations (Noriega, Gueimonde, 8 
Sánchez, Margolles, & de los Reyes-Gavilán, 2004). A significant part of our work has been 9 
focused on the couple Bifidobacterium animalis subsp. lactis IPLA4549 and its derivative 10 
strain B. animalis subsp. lactis 4549dOx. Strain 4549dOx displayed enhanced resistance to 11 
the GIT conditions (mainly low pH in the stomach, high bile salt concentration in the intestine 12 
and digestive enzymes), mainly linked to an increase in the membrane-bound F1-F0-ATPase 13 
activity, as well as to changes on the glycolytic flux (Sánchez et al., 2007; Sánchez, de los 14 
Reyes-Gavilán, & Margolles, 2006; Sánchez, Ruiz, de los Reyes-Gavilán, & Margolles, 15 
2008). B. animalis subsp. lactis is the most common Bifidobacterium species included in 16 
fermented dairy products, due to its good tolerance to both acidic and oxidative stress 17 
(Gueimonde, Noriega, Margolles, de los Reyes-Gavilán, & Salminen, 2005; Masco, 18 
Crockaert, van Hoorde, Swings, & Huys, 2007; Vernazza, Gibson, & Rastall, 2006), being 19 
able to maintain higher viability during product storage than other species (Jayamanne, & 20 
Adams, 2006) 21 
In the present study, we aimed to characterise the technological and some probiotic 22 
capabilities of the strains B. animalis subps. lactis IPLA4549 and its bile-adapted derivative 23 
4549dOx (Ruas-Madiedo, Hernández-Barranco, Margolles, & de los Reyes-Gavilán, 2005). 24 
The study was carried out in order to assess whether the acquisition of the bile resistance 25 
 4
phenotype might confer additional advantages for the inclusion of bile-adapted strains in 1 
fermented dairy products.  2 
 3 
2. MATERIAL AND METHODS 4 
2.1. Bifidobacteria strains 5 
The parental strain B. animalis subsp. lactis IPLA4549 and its bile-adapted derivative 6 
strain 4549dOx were used in this study. Bifidobacteria were cultured in MRSC [MRS (Biokar 7 
Diagnostics, Beauvais, France) with 0.05% (w/v) L-cysteine (Sigma Chemical Co., St. Louis, 8 
MO, USA)] and incubated for 24 h at 37ºC in the anaerobic chamber MG500 (Don Whitley 9 
Scientific, West Yorkshire, UK) under 10% (v/v) H2, 10% CO2 and 80% N2. Cultures were 10 
collected by centrifugation (10,000 g, 20 min, 5ºC), washed twice with PBS solution and 11 
resuspended (10-fold concentration) in sterile (11 % w/v) reconstituted skimmed milk 12 
(Difco®, Becton Dickinson, Franklin Lakes, NJ, USA). Finally, bacterial suspensions were 13 
lyophilised (Freezemobile 12EL, Virtis, Gardiner, NY, USA) for 24 h. 14 
2.2. Manufacture of fermented milk 15 
Two yoghurt starters were used for the manufacture of fermented milk: Fermovac® 16 
1000 V9 (containing Streptococcus thermophilus) and Fermovac® 1000 MSK R1 (containing 17 
S. thermophilus and Lactobacillus delbrueckii subsp. bulgaricus) from Danisco (Copenhagen, 18 
Denmark). Both starters were separately propagated (1% w/v) in skimmed milk overnight at 19 
37ºC. Cultures were then mixed in equal amounts and used to inoculate (2% v/v) whole milk 20 
supplemented with 1% skimmed milk powder previously pasteurised at 85ºC for 30 min. 21 
When appropriate, lyophilised bifidobacteria strains were added to a final concentration of 22 
108 cfu mL-1 just after the inoculation with the yoghurt starter mixture. Milk fermentations 23 
were carried out in a water bath at 42ºC until they reached a pH = 5.0 ± 0.1 and, afterwards, 24 
each fermented milk type was separated in several aliquots which were stored at 4ºC for 24 25 
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days. Three types of fermented milk were manufactured in triplicate: control (containing the 1 
yoghurt starter mixture), IPLA4549 (containing the yoghurt starter mixture and B. animalis 2 
IPLA4549) and 4549dOx (containing the yoghurt starter mixture and B. animalis 4549dOx). 3 
Several samples were collected at different points: after milk inoculation (0 h), after 1 h of 4 
fermentation, at the final fermentation (FF) time, and after 2, 10, 18 and 24 days of 5 
refrigeration.  6 
Bacterial counts and pH were determined at each sampling point using different 7 
growth media and culturing conditions. After serial dilutions of samples in Ringer solution 8 
(Merck, Darmstadt, Germany), S. thermophilus and L. delbrueckii subsp. bulgaricus were 9 
enumerated by spread plating on agar-M17 (Oxoid Ltd., Basingstoke, Hampshire, UK) or 10 
agar-MRS, respectively. All plates were incubated at 37ºC for 48 h. Bifidobacterium strains 11 
were counted in the same way in agar-MRSC-LP [MRSC supplemented with 0.2 % (w/v) 12 
lithium chloride and 0.3% sodium propionate (Sigma)] after growing in an anaerobic chamber 13 
at 37ºC for 72 h. The residual lactose and the accumulated galactose, as well as the production 14 
of acetic and lactic acids were quantified by HPLC and the production of volatile compounds 15 
by means of GC-MS as previously reported (Salazar et al., 2009). Results were expressed as 16 
mM for sugar and organic acids and in μM for volatile compounds.  17 
2.3. Resistance to the chemically simulated gastrointestinal transit 18 
The survival of the bifidobacteria strains during the passage through the 19 
gastrointestinal tract (GIT) was studied in an in vitro model that chemically simulates the 20 
physiological conditions, which had been modified from that previously described 21 
(Fernández, Boris, & Barbés, 2003). The following components were used: (i) simulated 22 
gastric juice (GJ) containing 125 mM NaCl, 7 mM KCl, 45 mM NaHCO3 and 0.3% pepsin 23 
(Sigma) adjusted with HCl to pH 2.0 or to pH 3.0, (ii) simulated duodenal juice (DJ) 24 
containing 1% bovine bile (Sigma) adjusted with 10 N NaOH to pH 8.0, and (iii) simulated 25 
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intestinal juice (IJ) containing 0.3% bovine bile, 0.1% pancreatin (Pancreas acetone powder 1 
porcine, Type I, Sigma, Catalogue number P4251) pH 8.0. To simulate the GIT transit 2 
conditions, bifidobacteria from 24 h MRSC-grown cultures of the parental and bile-adapted 3 
derivative were harvested by centrifugation (10,000 g, 15 min, 5ºC), washed twice with 4 
0.85% NaCl and resuspended in three types of GJ: pH 2.0, pH 3.0 and pH 2.0 containing 10% 5 
w/v skimmed milk powder. The three bacterial suspensions of each strain were then incubated 6 
for 180 min at 37ºC with stirring (200 rpm). Afterwards, samples were centrifuged (10000 g, 7 
15 min), cells were resuspended in DJ and incubated for 10 min at 37ºC in an anaerobic 8 
chamber. After this step cells were again centrifuged, each resuspended in IJ and incubated 9 
for 180 min at 37ºC in anaerobic conditions. Viable cell counts were obtained from the initial 10 
cultures, after 90 and 180 min of GJ challenge, after 10 min of DJ challenge, and after 90 and 11 
180 min of IJ challenge. Results were expressed as Log cfu mL-1 and the percentage of 12 
survival was calculated from the viable counts recovered after the complete chemically 13 
simulated GIT transit with respect to the initial counts (% cfu recovered bacteria / cfu initial 14 
bacteria). Experiments were carried out in triplicate.  15 
2.4. Adhesion to the HT-29-MTX cell line 16 
The adhesion capability of the strains was assessed with the epithelial intestinal cell 17 
line HT29-MTX which was kindly supplied by Dr. T. Lesuffleur (INSERM U843 Paris, 18 
France). This cell line is able to constitutively produce mucin (Lesuffleur, Barbat, Dussaulx, 19 
& Zweibaum, 1990). The cell line was maintained in DMEM medium supplemented with 20 
10% (v/v) heat-inactivated bovine foetal serum and a mixture of antibiotics to give a final 21 
concentration of 50 μg mL-1 penicillin, 50 μg mL-1 streptomycin, 50 μg mL-1 gentamicin and 22 
1.25 μg mL-1 amphotericin B. All media and reagents were purchased from Sigma and 23 
incubations took place at 37ºC, 5% CO2 in a SL Waterjacked CO2 Incubator (Sheldon Mfg. 24 
Inc., Cornelius, Oregon, USA). Culture media were changed every two days and the cell lines 25 
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were trypsinized with 0.25% trypsin-EDTA solution (Sigma) following standard procedures 1 
(Sánchez et al., 2009). For experiments, 105 cells mL-1 were seed in 24-well plates and 2 
incubated to confluence (reaching about 107 cells mL-1) for 13±1 days.   3 
Parental and bile-adapted derivative strains and the reference strain B. animalis subsp. 4 
lactis Bb12 were grown in MRSC for 24 h. Cultures were harvested by centrifugation, 5 
washed twice with Dulbecco’s PBS buffer (Sigma) and resuspended in DMEM without 6 
antibiotics at a concentration of about 108 cfu mL-1. HT29-MTX monolayers were washed 7 
twice with Dubelco’s PBS to remove the antibiotics and then bacterial suspensions were 8 
added in a ratio of epithelial cells:bacteria of 1:10. Plates were incubated for 1 h at 37°C, 5% 9 
CO2 in a Heracell® 240 incubator (Thermo Electron LDD GmbH, Langenselbold, Germany). 10 
After the incubation period, supernatants were removed and wells were softly washed three 11 
times with Dubelco’s PBS buffer to remove the non-attached bacteria. Afterwards, the 12 
monolayers were trypsinized and bacterial counts were carried out in agar-MRSC to 13 
determine the number of adhered bacteria. Results were expressed as the percentage of 14 
bacteria adhered with respect to the amount of bacteria added (% cfu bacteria adhered / cfu 15 
bacteria added). Experiments were carried out in duplicate (using two HT29-MTX plates) and 16 
in each plate the strains were also tested in duplicate. 17 
2.5. Statistical analysis 18 
Data were statistically analysed using the SPSS 11.0 software for Windows (SPSS 19 
Inc., Chicago IL, USA) by means of one-way ANOVA tests independently performed at each 20 
sampling point. When needed, the mean comparison LSD (least-significant difference, p< 21 
0.05) test was used to assess differences among fermented milk or strains.  22 
23 
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3. RESULTS AND DISCUSSION  1 
3.1. Growth and metabolic activity in milk 2 
 The pH and bacterial dynamics of milk fermented with a starter mixture of S. 3 
thermophilus and L. delbrueckii subsp. bulgaricus containing the parental strain B. animalis 4 
subsp. lactis IPLA4549 or its bile-adapted derivative 4549dOx is depicted in Figure 1. No 5 
remarkable statistical differences were detected among control and fermented milk containing 6 
bifidobacteria during milk fermentation or during cold storage of the fermented products. 7 
Once S. thermophilus and L. delbrueckii subsp. bulgaricus reached their maximum counts 8 
(8.45±0.06 and 7.56±0.02 Log cfu mL-1, respectively) (average counts of all fermentations) 9 
they remained without noticeable variations until the end of the storage period, although in all 10 
cases a trend towards a slight decrease on the viability is observed, regardless the type of 11 
fermented milk. Thus, these data indicates that the presence of the bifidobacteria strains did 12 
not modify the growth and acidification capability of the starter mixture used except in the 13 
first hour of fermentation, in which a quicker acidification in the control milks was observed.  14 
In the same way, counts of bifidobacteria did not suffer significant variations during 15 
fermentation. It has been suggested that the recommended daily intake for probiotic strains is 16 
around 109 viable bacteria per day (Ouwehand, Salminen, & Isolauri, 2002), thus both 17 
parental and bile-adapted B. animalis subsp. lactis strains complied with the 18 
recommendations in the fermented milk assayed. In fact, this species is widely present in 19 
commercial probiotic fermented milk (Gueimonde et al., 2004) probably because it tolerates 20 
technologically adverse conditions, such as low pH and the presence of oxygen, better than 21 
other bifidobacteria species (Masco, Crockaert, van Hoorde, Swings, & Huys, 2007; Simpson, 22 
Stanton, Fitzgerald, & Ross, 2005). 23 
 The metabolic activity of the strains in the fermented milk was assessed by studying 24 
the evolution of the saccharides and organic acids (Table 1), as well as of some volatile 25 
 9
compounds (Table 2). Similar trends were observed, whether fermented milks contained or 1 
not bifidobacteria (Table 1), although the absence of bifidobacteria reduced the post-2 
acidification process at days 10 and 18 of cold storage (Table 1). Noticeably, acetic acid 3 
accumulation was slightly higher in the fermented milk samples that contained bifidobacteria, 4 
which is in agreement with its fermentative metabolism (Sánchez et al., 2007). This suggests 5 
that the co-cultivation of bifidobacteria and starter strains did not produce, in general, any 6 
antagonist or synergic effect that could influence the evolution of these metabolites.  7 
Regarding the main volatile compounds produced (Table 2), diacetyl synthesised by 8 
the starter strains increased during the fermentation and cold storage and the levels were not 9 
affected by the presence of the bifidobacteria strains (p> 0.05). However, significant 10 
differences (p≤ 0.05) in the levels of acetaldehyde and ethanol were detected among the three 11 
fermented milk types. In general, lower concentrations of these metabolites were detected in 12 
the control batch with respect to the batches containing bifidobacteria. Fermented milk 13 
containing the 4549dOx strain, presented higher levels of acetaldehyde at the end of the 14 
refrigeration period This fact could reflect the modification of glucose metabolism that occurs 15 
in the bile-adapted derivative strain as a consequence of the adaptation to bile (Ruas-Madiedo, 16 
Hernández-Barranco, Margolles, & de los Reyes-Gavilán, 2005; Sánchez, et al., 2007).  17 
 18 
3.2. Probiotic selection criteria 19 
As previously stated, one of the criteria for the selection of orally-delivered probiotic 20 
strains is their ability to survive the adverse conditions of the gut. Figure 2 shows the 21 
dynamics of the parental strain B. animalis subsp. lactis IPLA4549 and its bile-adapted 22 
derivative 4549dOx at different steps during the chemically simulated GIT transit. The 23 
greatest difference between both strains was detected when they were challenged to GJ pH 2.0 24 
during 180 min. A drastic reduction of counts was detected in the parental strain (6.9 Log cfu 25 
 10
mL-1) whereas in the bile-adapted derivative was lower (3.6 Log cfu mL-1). This different 1 
behaviour of the 4549dOx strain could be due to its acid cross-resistance earned as a 2 
consequence of the acquisition of bile resistance (Noriega, Gueimonde, Sánchez, Margolles, 3 
& de los Reyes-Gavilán, 2004), which is produced by an increase in its F1F0-ATPase activity 4 
with respect to the parental strain (Sánchez, de los Reyes-Gavilán, & Margolles, 2006). 5 
Meanwhile, the acidic challenge at higher pH (pH 3.0) or at pH 2.0 in the presence of 10% 6 
skimmed milk (which increased the pH of the GJ to 4.0) did not produce a loss in the viability 7 
of both strains after 180 min of GJ stress. Probably, this is due to the high intrinsic resistance 8 
to acidic pH of the species B. animalis (Matsumoto, Ohishi, & Benno, 2004). After the GJ pH 9 
2.0 and DJ (1% bile salt) challenges, the counts of 4549dOx strain showed lower decreases 10 
than strain IPLA4549, but decreased abruptly after the subsequent IJ challenge (0.3% bile salt 11 
and 0.1% pancreatin) reaching the lowest counts after 180 min of exposure. No viability loss 12 
was detected at the end of the process when the 4549dOx strain was initially challenged to GJ 13 
pH 3.0 or pH 2.0 + 10% skimmed milk, probably because the strain was initially less stressed 14 
in these conditions. Regarding the parental strain IPLA4549, at acidic pH 3.0 and after the DJ 15 
and IJ challenges the counts decreased near 1 Log unit due to the bile stress, whereas in the 16 
presence of milk the strain kept its viability probably because of the protective effect of milk 17 
components. Finally, the calculation of the bacterial survival after the whole GIT transit 18 
showed that when the strains were initially challenged to GJ pH 2.0 they hardly survived 19 
(counts lower than 5x102 cfu mL-1). However, the same GJ in the presence of 10% of 20 
skimmed milk considerably improved the bacterial survival and statistical differences (p< 21 
0.05) were detected between the parental and bile-adapted strains (% survival: 19.6±7.6 and 22 
60.0±25.3, respectively). Similar behaviour was detected when strains were initially 23 
challenged to GJ pH 3.0 (% survival: 9.5±4.5 and 52.6±25.9 for IPLA4549 and 4549dOx, 24 
respectively, p< 0.05). All these results showed that the bile-adapted 4549dOx strain survived 25 
 11
slightly better in vitro the adverse conditions of the GIT, thus probably being able to reach the 1 
colon in a higher number. In this way, other authors have shown that higher tolerance to bile 2 
also improves the resistance of Bifidobacterium breve UCC2003 to the murine GIT transit 3 
(Watson, Sleator, Hill, & Gahan, 2008). In addition, several articles reporting the survival of 4 
bifidobacteria after the GIT transit have been published in which different study approaches 5 
were carried out. Recently, using a bioreactor model of the stomach-intestine, it has been 6 
proven that B. animalis subsp. lactis is the species that shows the highest survival in 7 
comparison to other species of the genus Bifidobacterium (Ritter, Kohler, & von Ah, 2009). 8 
Another criterion for the selection of potential probiotic strains is their capability to 9 
transitory colonise the GIT. In our case, we studied the adhesion of both parental and bile-10 
adapted derivative strains to the epithelial intestinal line HT29-MTX, as the percentage of cfu 11 
adhered / cfu added bacteria. The results (IPLA4549 = 2.96 ± 1.74; 4549dOx = 5.58 ± 1.60) 12 
were compared with those of the reference strain B. animalis subsp. lactis Bb12 (% adhesion 13 
= 3.08 ± 1.37), which shows a good adherence capability to epithelial intestinal cell lines and 14 
to human mucus (de Palencia, López, Corbí, Peláez, & Requena, 2008; He et al., 2001). No 15 
statistical differences (p> 0.05) were detected among the three strains, although the bile-16 
adapted 4549dOx strain showed a slightly higher (almost twice as much) percentage of 17 
adhesion than the parental and reference strains.  18 
 19 
4. CONCLUSIONS 20 
 We have studied the technological and probiotic potential of the bile-adapted strain B. 21 
animalis subsp. lactis 4549dOx with respect to its parental strain IPLA4549. The bile-adapted 22 
derivative strain showed better ability to survive in simulated GIT conditions, and slightly 23 
higher adhesion capability to the model epithelial intestinal line HT29-MTX. Both parental 24 
and bile-resistant derivative strains were able to keep their viability for the shelf-life of the 25 
 12
fermented milk. The strain 4549dOx seems to be more suitable for its inclusion on the 1 
formulation of functional foods.  2 
 3 
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Table 1 1 
Residual lactose, and production of lactic and acetic acids (mM) in milk fermented with a commercial starter of S. thermophilus and L. 2 
delbrueckii subsp. bulgaricus (control) in the presence of B. animalis subsp. lactis IPLA4549 (IPLA4549) or its bile-resistant derivative 3 
4549dOx (4549dOx) during the fermentation process and during the cold storage of the fermented products.  4 
Period Time Sample Lactose Lactic acid Acetic acid 
Fermentation 0h Control 148.65±9.16 2.46±0.23 0.13±0.07 
1h Control 145.36±10.32 17.80±6.72 0.06±0.09 
IPLA4549 137.88±13.98 10.52±5.47 0.46±0.51 
4549dOx 136.52±36.86 12.92±4.13 0.42±0.35 
Final Control 125.09±6.08 121.42±10.10 0.08±0.12b 
IPLA4549 111.35±23.59 104.93±15.99 1.79±0.68 a 
4549dOx 103.57±30.30 140.37±47.32 0.71±0.51 ab ** 
Cold storage 2d Control 111.64±11.32 124.60±7.64 0.07±0.10 b 
IPLA4549 105.65±25.09 116.65±25.36 1.49±1.05 a 
4549dOx 90.01±19.37 111.28±5.25 0.74±0.52 a ** 
10d Control 116.35±2.46 164.59±7.01 0.12±0.17 b 
IPLA4549 92.28±32.82 129.12±43.30 1.26±0.94 a 
4549dOx 95.98±25.96 87.30±34.11 0.46±0.34 ab  * 
18d Control 95.05±16.88 140.84±19.05 0.07±0.10 b 
IPLA4549 95.98±25.96 138.72±35.18 1.38±0.98 a 
4549dOx 78.33±24.70 86.80±15.45 0.62±0.45 ab ** 
24d Control 70.05±28.50 104.40±40.97 0.00±0.00 
IPLA4549 101.57±20.06 148.87±27.90 1.57±1.11 
4549dOx 77.23±26.94 152.85±44.85 1.07±0.93 
One-way ANOVA: * p<0.05. Within each time period the values that do not share a common superscript are statistically different (p<0.05) according to the LSD (least 5 
significant difference) mean comparison test.  6 
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Table 2 1 
Production of volatile compounds (μM) in milk fermented with a commercial starter of S. 2 
thermophilus and L. delbrueckii subsp. bulgaricus in the presence of B. animalis subsp. lactis 3 
IPLA4549 or its bile-resistant derivative 4549dOx during the fermentation process and during 4 
the cold storage of the fermented products.  5 
 6 
Period Time Sample Acetaldehyde Ethanol Diacetyl 
Fermentation 0 h Control 1.36±0.22 16.32±5.50 1.17±0.16  
 1 h Control 
IPLA4549 
4549dOx 
6.09±3.52 
14.91±9.84 
12.96±9.81 
11.00±2.11 
16.47±4.22 
12.33±4.62 
1.92±0.94 
1.12±0.23 
0.97±0.14 
 Final Control 
IPLA4549 
4549dOx 
113.73±10.39 
156.12±35.48 
151.65±38.14 
16.18±0.21 a 
73.46±24.58 b 
57.42±16.81 b 
** 
2.85±0.72  
3.88±0.30  
4.83±1.53  
Cold storage 2 d Control 
IPLA4549 
4549dOx 
92.66±19.86 
110.75±20.73 
129.01±34.54 
35.46±7.76 a 
136.64±19.59 c  
67.36±18.01 b 
*** 
6.28±1.43 
6.75±1.89 
6.70±1.04 
 10 d Control 
IPLA4549 
4549dOx 
95.63±30.63 
106.98±18.35 
96.07±28.62 
49.68±11.99 a 
181.04±63.16 b 
61.91±15.53 a 
** 
10.87±2.72 
8.00±3.34 
9.44±2.03 
 18 d Control 
IPLA4549 
4549dOx 
72.67±14.48 a 
89.00±19.28 a 
131.95±19.85 b 
** 
45.84±7.07 a 
140.26±17.69 c 
87.66±35.44 b 
** 
9.13±2.61 
8.61±2.20 
11.05±1.92 
 24 d Control 
IPLA4549 
4549dOx 
66.91±11.32 a 
103.37±35.72 ab 
121.58±25.65 b 
* 
35.16±6.57 a 
148.62±17.80 c 
67.27±29.52 b 
*** 
12.75±3.38 
11.77±3.58 
9.81±2.09 
 7 
One-way ANOVA: * p<0.05, ** p<0.01, *** p<0.001. Within each time period the values that do not share a 8 
common superscript are statistically different (p<0.05) according to the LSD (least significant difference) mean 9 
comparison test.  10 
11 
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FIGURE CAPTATIONS 1 
Figure 1  2 
Counts (Log cfu mL-1) of S. thermophilus (A). L. delbrueckii subsp. bulgaricus (B). or B. 3 
animalis subsp. lactis (C). in milk fermented with a commercial starter of S. thermophilus and 4 
L. delbrueckii subsp. bulgaricus in the presence of B. animalis subsp. lactis IPLA4549 or its 5 
bile-resistant derivative 4549dOx. Samples were taken during the fermentation process and 6 
during the cold storage of the fermented products. and pH (D) was also monitored. The final 7 
fermentation period (FF) was 277 ± 21 min. Fermented milk types: control (white bars). 8 
IPLA4549 (grey bars) and 4549dOx (black bars). At each sampling point. columns that do not 9 
share a common letter are statistically different (p<0.05).  10 
 11 
Figure 2  12 
Counts (Log cfu mL-1) of B. animalis subsp. lactis IPLA4549 (black circles) and its bile-13 
resistant derivative 4549dOx (white squares) along the chemically simulated gastrointestinal 14 
transit. Three simulated gastric juice conditions were tested: pH 2.0 (A). pH 3.0 (B) and pH 15 
2.0 + 10% skimmed milk (C). The modal value of the coefficient of variation (SD/mean) of 16 
these results was 4%. 17 
18 
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